Biotech
Aug. 11, 2011
Sam Zucker
The past two years have brought some significant changes to the biotech arena, Zucker said.
"There is widespread awareness that the traditional model of biotech is largely broken," he said. "Risk has gone up considerably. It's harder to get a drug or device approved by the FDA."
If launched today, many of the traditional biotechs that were successful in the past wouldn't get funding, Zucker added.
Instea...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In